CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$56.09 USD
-0.17 (-0.30%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $56.05 -0.04 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
F Value B Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRSP 56.09 -0.17(-0.30%)
Will CRSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
New Strong Sell Stocks for August 1st
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views?
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
Other News for CRSP
Cathie Wood Loads Up Millions on Google, AMD in Bold ARK Shift
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics
Undercovered Dozen: Power Solutions, Porsche, B2Gold And More
Cathie Wood Doesn't Need Tesla To Win—ARKK Delivers A Blowout While EV Giant Idles
CRSP September 5th Options Begin Trading